Key facts
- This page summarizes David W. Gryska's Form 4 filing for GW PHARMACEUTICALS PLC.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 May 2021, 16:19.
David W. Gryska - 05 May 2021 Form 4 Insider Report for GW PHARMACEUTICALS PLC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 05 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 May 2021, 16:19:12 UTC
- Next SEC filing
- 18 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ David W. Gryska
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David W. Gryska filed Form 4 for GW PHARMACEUTICALS PLC on 07 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GWPH
transaction
Derivative
Share Options
Disposed to Issuer
- Transaction value
- Shares
- -35,208
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 05 May 2021
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 35,208
- Exercise price
- $0.001700
- Footnotes
- F1, F2, F3
GWPH
transaction
Derivative
Share Options
Disposed to Issuer
- Transaction value
- Shares
- -22,464
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 05 May 2021
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 22,464
- Exercise price
- $0.001700
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David W. Gryska is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Footnote F2
Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Footnote F3
These stock options were granted with automatic vesting on exercisable date.